<DOC>
	<DOCNO>NCT01921270</DOCNO>
	<brief_summary>The purpose study study efficacy , safety , proper dose AbobotulinumtoxinA ( Dysport ) use Oromandibular Dystonia ( OMD ) . The study hypothesis one dosing level use adequate safety efficacy .</brief_summary>
	<brief_title>Dysport Treatment OMD</brief_title>
	<detailed_description>Study Design : Interventional , single site , prospective study 2 part : 1 . Dose rag ( aim 1 ) : 3 oromandibular Dystonia ( OMD ) group undergo 3 different Dysport® dosages step-wise approach base safety response . 6 week duration 3 group . 2 . Efficacy &amp; safety assessment Dysport® select dose study part 1 ( aim 2 ) : 1 single arm OMD subject . 12 week duration . Study Specific Aims : Aim 1 : To determine best dose range Dysport® treatment OMD In order address Aim 1 , patient OMD previously treat Botox® ( onabotulinumtoxinA ) respond recruit study . The muscle inject tailor individual 's presentation injector 's discretion , muscle chosen give set amount Dysport® ( abobotulinumtoxinA ) ( see table 2 ) . The subject inject Dysport® , unblinded open-label disclosure . There three dose level three subject inject ( OMD type group : 2 jaw open + 1 jaw closing ) . This optimal dosage safe dosage provide adequate efficacy . This base Clinical Global Impression Scale 's Efficacy Index . Subjects Aim 1 offer enrollment Aim 2 . Aim 2 : To determine efficacy safety Dysport® treatment oromandibular dystonia 20 subject include second part study inject determine optimal dosage find end first study part . They would inject Aim 2 least 12 week pass , give effect prior injection either completely abate least declined significantly . The 9 subject Aim 1 offer enter study part 2 unless severe adverse event ( AE ) , ongoing AE AE consider inappropriate study continuation . Their previous injection Dysport® confound result Aim 2 since Botox® Dysport® minimal clinical effect 12 week injection . Since local population suffer OMD small , inclusion Aim 1 subject Aim 2 would lead much rapid completion recruitment . In Aim 1 Aim 2 , safety efficacy record subject undergo injection . All subject examine videotaped injection visit , 6 12 week injection standardize protocol . The primary outcome blind examination score videos perform study complete . The evaluator two different movement disorder expert , otherwise involve study , review videotape examination , present random order , use Global Dystonia Rating scale ( GDS ) . They rate dystonia baseline ( injection visit ) 6 week injection . The change GDS score baseline 6 week injection best objective measure efficacy serve study 's primary endpoint . The investigator choose GDS dystonia scale ease use , sensitivity clinical change continuous rating system , internal consistency , inter-rater reliability .</detailed_description>
	<mesh_term>Dystonia</mesh_term>
	<mesh_term>Dystonic Disorders</mesh_term>
	<mesh_term>Movement Disorders</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<criteria>diagnosis primary tardive OMD moderate severe severity , define GDS score ≥4 either `` low face '' `` jaw tongue '' section age &gt; 18 year capability attend schedule visit previously inject onabotulinumtoxinA respond treatment , least 12 week post last injection Women childbearing age need use contraception order include . Existence systemic disease could confound evaluation previous placement Deep Brain Stimulation electrodes treat dystonia concomitant oral medication could interfere action botulinum toxin Type A ( e.g. , aminoglycosides ) unstable dosage medication prescribe treat dystonia ( e.g. , benzodiazepine , baclofen anticholinergic ) know hypersensitivity botulinum toxin preparation allergy cow 's milk protein immunoresistance form botulinum toxin type A existence concomitant neuromuscular disorder ( e.g. , Myasthenia Gravis LambertEaton syndrome , etc ) infection propose injection sit pregnant woman woman childbearing age NOT contraception breastfeed woman inability comply schedule visit patient previously inject botulinum toxin type A respond</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Oromandibular Dystonia</keyword>
	<keyword>Oral Dystonia</keyword>
	<keyword>Tardive Dystonia</keyword>
	<keyword>botulinum toxin</keyword>
	<keyword>abobotulinumtoxinA</keyword>
</DOC>